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Two genes are called synthetic lethal (SL) if their simultaneous mutations lead to cell death, but each individual
mutation does not. Targeting SL partners of mutated cancer genes can kill cancer cells specifically, but leave normal
cells intact.We present an integrated approach to uncoveringSLpairs in colorectal cancer (CRC). Screening verified SL
pairs using microarray gene expression data of cancerous and normal tissues, we first identified potential functionally
relevant (simultaneously differentially expressed) gene pairs. From the top-ranked pairs, ~20 genes were chosen for
immunohistochemistry (IHC) staining in 171 CRC patients. To find novel SL pairs, all 169 combined pairs from the
individual IHC were synergistically correlated to five clinicopathological features, e.g. overall survival. Of the 11
predicted SL pairs, MSH2-POLB and CSNK1E-MYC were consistent with literature, and we validated the top two
pairs, CSNK1E-TP53 and CTNNB1-TP53 using RNAi knockdown and small molecule inhibitors of CSNK1E in isogenic
HCT-116 andRKOcells. Furthermore, synthetic lethality ofCSNK1E and TP53was verified inmousemodel. Importantly,
multivariate analysis revealed that CSNK1E-P53, CTNNB1-P53, MSH2-RB1, and BRCA1-WNT5A were independentry rate; TD, tumor-dependent; SL, synthetic lethal
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442 CSNK1E/CTNNB1 are synthetic lethal to TP53 Tiong et al. Neoplasia Vol. 16, No. 5, 2014prognosis markers from stage, with CSNK1E-P53 applicable to early-stage and the remaining three throughout all
stages. Our findings suggest that CSNK1E is a promising target for TP53-mutant CRC patients which constitute ~40%
to 50% of patients, while to date safety regarding inhibition of TP53 is controversial. Thus the integrated approach is
useful in finding novel SL pairs for cancer therapeutics, and it is readily accessible and applicable to other cancers.
Neoplasia (2014) 16, 441–450Introduction
Colorectal cancer (CRC) is the third most common cancer worldwide
with nearly 1 million annual incidences and 400,000 yearly deaths
[1]. Multiple genes are mutated during tumorigenesis, with those
contributing to tumor formation and growth being called cancer
genes [2], which can be categorized into oncogenes, tumor suppressor
genes and stability genes. Mutant oncogene and tumor suppressor
gene frequently implicated in colorectal cancer are CTNNB1 and
TP53, respectively, and are involved in cancer cell proliferation,
while stability genes such as MSH2 are responsible for the
safeguarding of genomic integrity. Although to date some therapeu-
tics directed against oncogenes have led to increases in patient
survival, many fail due to intrinsic or adaptive resistance of cancer cells
to the therapeutics. For example, when CRC patients are treated with
cetuximab (EGFR inhibitor), resistance arise due to crosstalk between
Src family kinases and EGFR [3].
Two genes are called synthetic lethal (a type of genetic interaction [4])
when their simultaneous mutations lead to cell death, while each single
mutation does not. Genome-scale mappings of SLs in S. cerevisiae were
obtained through high-throughput synthetic genetic array analyses [5–7].
Wong and colleagues successfully predicted synthetic sick or lethal (SSL)
interactions in S. cerevisiae by integrating multiple types of data, e.g., gene
expression, protein-protein interaction and properties of network
topology of gene triples [8]. About 80% of SSL interactions therein
were discovered successfully via validating b20% of the predicted
interactions. In C. elegans, Zhong and Steinberg [9] computationally
integrated interactome, gene expression and phenotype data to predict
genome-wide genetic interactions; they further experimentally verified the
predictions for two human disease-associated genes.
The concept of synthetic lethality can be applied to exploit cancer-cell
specific mutations for cancer therapeutics [10]. Targeting synthetic
lethal (SL) partners of mutated cancer genes will specifically kill cancer
cells bearing the mutations but spare normal cells. Therefore, synthetic
lethality strategy offers an elegant alternative for non-druggable mutant
tumor suppressor genes and difficult-to-target-directly oncogenes, such
as TP53 and KRAS, respectively, by targeting their SL partners. Lately,
pioneering studies of SL partners in BRCA1 and BRCA2-deficient
cancer cells identified PARP1 as a promising drug target [11,12]. The
clinical relevance of synthetic lethality has been rapidly recognized.
Multiple phase II and III clinical trials of PARP inhibitors were
conducted for breast and ovarian cancer patients with BRCA1 or
BRCA2 mutation [13,14].Over the last few years, genes having SL
interactions (SLs) in cancers have been actively studied using individual
RNAi experiments, or by large scale RNAi screenings that uncover
multiple SL gene pairs [15–17], which in general were centered on one
gene. Astsaturov and colleagues identified SLs in human by combining
both computational and experimental approaches [18].They first
combined pathway maps, protein-protein interactions, gene expression
data and human orthologs of Drosophila Egfr genetic interactionpartners, to predict 2689 SL candidates of EGFR. They then selected
683 candidates for RNAi screening, by their appearance in at least two
of these information sources or by prior biological knowledge, which
resulted in 61 SLs. Wang and Simon [19] developed a promising
computational approach to prefilering p53 SL genes before
RNAi screening. They analyzed five gene expression datasets
from NCI-60 panel, The Cancer Genome Atlas and Cancer Cell
Line Encyclopedia. Kinase-encoding genes highly expressed in
functional p53-mutant samples versus samples without functional
p53 mutation were first identified, and were further prioritized
by inferred significant networks, functional annotation and drug
sensitivity analysis.
To augment these RNAi-based experimental methods, we have
developed a cost-effective approach, which integrates computational
and experimental methods to uncover SL gene pairs for colorectal
cancer. Our approach incorporates SL pairs in literature, microarray
gene expression data, protein expression (immunohistochemistry
[IHC] of CRC tissues) and phenotypic (clinicopathological factors)
data. Let A-B denote a gene (protein) pair of A and B henceforth.
Screening across 600+ previously verified SL pairs using microarray
gene expression data of cancerous and normal tissues (a pilot study),
we found that some SL gene pairs, such as BRCA1-PARP1 and TP53-
SGK2, were simultaneously differentially expressed in high percent-
ages in several cancerous tissues including CRC. Studies in S. cerevisiae
and C. elegans have also shown that co-expression of gene pairs may be
a relevant feature for predicting genetic interactions genome-wide
[6,8,9]. Therefore, these verified SL pairs with differential gene
expression patterns were classified as initial candidate tumor-
dependent (TD) gene pairs (Table 1), from which we selected 17
genes to conduct IHC staining at multiple cellular locations. Next, to
find novel SL pairs, we combined all possible pairs from the ~20
individual IHCs giving a total of 169 protein pairs. Because protein
pairs related to tumor cell viability and malignancy may be indicated
by their correlation with clinicopathological features obtained from
CRC patients, we then tested each of these protein pairs for synergistic
correlation with clinical features of the same set of patients to identify
TD pairs, which are our predicted SL pairs. The cancer phenotypes
observed (e.g., overall survival) suggested that the tumor cells may
depend on each protein pair for viability and, therefore, simulta-
neously mutating each TD pair may kill tumor cells. RNAi, small-
molecule inhibitor and in vivo experiments were then performed
to validate the top two predicted SL partners of TP53, which is
involved in multiple pathways, leading to challenges in
therapeutic development. A graphical illustration of our approach
is presented in Supplementary Figure W1. Finally, we identified
protein pairs whose abnormal IHCs were correlated with poor
patient survival, and analyzed the IHCs of the 169 protein pairs
and clinicopathological features to find independent prognostic
markers of CRC patients.
Table 1. Initial panel of candidate TD pairs for CRC, showing the percentages of the four gene expression patterns.
TD pairs Percentages of gene pairs from 70 Asian CRC versus 12 non-cancerous tissues that were expressed 2-fold or more
Gene 1 Gene 2 (up, up) pattern (up, down) pattern (down, up) pattern (down, down) pattern Permutation P value * FDR †
FEN1 RAD54B 0.67 ‡ 0.00 0.00 0.00 0.0001 1×10-5
BRCA2 PARP1 0.34 0.00 0.00 0.00 0.0001 1×10-5
MSH2 POLB 0.33 0.00 0.00 0.00 0.0001 1×10-5
BRCA1 PARP1 0.26 0.00 0.00 0.00 0.0001 1×10-5
MYC AURKB 0.17 0.00 0.00 0.00 0.0001 1×10-5
RB1 SKP2 0.06 0.00 0.00 0.00 0.0002 2×10-5
CSNK1E CTNNB1 0.03 0.00 0.00 0.00 0.0001 1×10-5
BCR WNT5A 0.03 0.01 0.00 0.00 0.0001 1×10-5
KRAS SLKRAS
§ 0.01 0.00 0.00 0.00 0.0001 ~ 0.7200 1×10-5 ~ 0.0303
TP53 SGK2 0.00 0.33 0.00 0.20 0.0004 3×10-5
KRAS SLKRAS
¶ 0.00 0.01 0.00 0.00 0.0001 ~ 0.8540 1×10-5 ~ 0.0351
PTEN PARP1 0.00 0.00 0.01 0.00 0.0001 1×10-5
ABL1 WNT5A 0.00 0.00 0.01 0.00 0.0043 0.0003
* This P value was for the highest percentage of the four patterns computed by permutation test with 10,000 repeats.
† FDR was estimated by q-value.
‡ The four fractions are computed from gene pairs that were 2-fold differentially expressed, thus they might not sum up to 100%.
§ 57 verified KRAS SL pairs were identified in the (up, up) pattern.
¶ 19 verified KRAS SL pairs were identified in the (up, down) pattern.
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Computation of Gene Expression Profiles of Colorectal Cancer
Versus Non-Cancerous Tissues
We filtered gene expression data sets according to the following
parameters: both cancer and non-cancerous tissues, no treatments, no
metastasis and affymetrix chips (up to Nov. 2010). The CRC gene
profiles satisfying the above criteria were downloaded from the Gene
Expression Omnibus database [20]. Because mutated genes involved
in the oncogenesis of a given cancer are known to vary between
patients of different ethnic backgrounds [21], we collected gene
expression data from patients of Han Chinese origin (GSE 9348 in
[22]), the same ethnic background as the IHC and clinicopathological
data used in later sections. Gene expression profiles from all 70
colorectal cancer and 12 non-cancerous tissues in the dataset were first
quantile-normalized (expresso in R), then for a given gene the log
ratio of its expression in each cancer tissue versus that of the averaged
non-cancerous tissues was computed. The dataset used is shown in
Supplementary Dataset S1.
Inferring the Initial Panel of TD Gene Pairs for Colorectal
Cancer Using Microarray Gene Expression Data
We first collected 663 gene pairs whose SL interactions were either
validated using various human cancer cell lines [11,23] or genome-
wide RNAi knockdown [15,16] (Supplementary Table W1). For
each SL pair collected, the percentages of tissues in which both genes
were (up, up), (up, down), (down, up), or (down, down) were
computed, respectively. Next, the top-ranking 11 gene pairs and
several KRAS pairs were selected to make up the panel of initial
candidate TD pairs for CRC.
Permutation Test and False-Positive Rates of the Percentages of
Paired Gene Expression in Table 1
To assess the statistical significance (P value) of the percentages of the
(up, up) or (up, down) patterns of each gene pair in Table 1, for each
percentage we performed a permutation test to generate its nonpara-
metric distribution. The total rearrangements of the labels of (70) cancer
and (12) non-cancerous tissues was equal to 8270
 
, from which we
randomly chose 10,000 rearrangements. For each rearrangement wecomputed the percentage of a pair’s pattern to form its distribution, from
which we assessed the significance of an observed percentage. Next, we
applied q-value (qvalue in R; [24]) to estimate false discovery rate (FDR)
of the significance of the gene pairs and the predicted SL pairs in Tables 1
and 3, respectively.
Preparation of Tissue Microarrays
One hundred seventy-one representative cancer specimens
(Supplementary Table W2) were randomly chosen from hema-
toxylin and eosin–stained sections and confirmed by pathologists.
Four tissue cores (2 mm in diameter) were obtained from each
paraffin block from which three cores of cancerous and one core of
noncancerous tissues were cut longitudinally. The tissue cores
were set into new paraffin blocks using a fine steel needle to produce
tissue microarrays. This study was approved by the institutional review
board and ethics committee of Changhua Christian Hospital and the
institutional review board of Academia Sinica.
Immunohistochemistry
The sections (4 μm) of tissue microarray were deparaffinized in
xylene and hydrated in serial dilutions of alcohol. Endogenous
peroxidase activity was quenched by 3% H2O2. The sections were
performed by treatment with boiling citrate buffer (10 mmol/L) for
20 minutes for antigen retrieval. The tissues were then incubated with
17 primary antibodies (Supplementary Table W3). Incubation with
the primary antibody was carried out for 30 minutes at room
temperature, followed by rinsing three-times with phosphate-buffered
saline. The slides were incubated with a horseradish peroxidase/Fab
polymer conjugate (EnVision™ Detection systems Peroxidase/DAB,
Rabbit/Mouse [K5007 HRP; DaKo]) for another 30 minutes. After
rinsing, the chromogen was developed with 3,3′-diamino-benzidine
tetrahydrochloride as the substrate and hematoxylin as the counter-
stain. The staining intensity in the cancerous tissue was examined by
two pathologists (Kun-Tu Yeh and Tzu-Cheng Su). The scoring
criteria were similar to those in [25]. Specifically, the stain intensity
was graded as negative-0, indeterminate-±, weak positive-1+,
moderate positive-2+ or strong positive-3+. For staining intensity
negative-0, there is no expression of the detected protein; for
indeterminate-±, the staining is weak and its percentage cannot be
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expression of the detected protein in the cancer cells; for moderate
positive-2+, there is focal expression in 5% to 20% of the cancer cells;
for moderate positive-3+, there is diffuse expression over 20% of the
cancer cells. The staining intensity in the cancerous tissue was
categorized as overexpression or underexpression through comparison
with noncancerous colonic mucosa.
Fisher’s Exact Test
Fisher’s exact test was conducted to determine independence
between IHC expression levels of each predicted SL pair and clinic-
pathological features. IHC expression levels of each protein were
dichotomized into two classes, abnormal and normal, according to
the criteria in Table 2. Further, clinical factors of 171 CRC patients
were also dichotomized as follows; survival time b3 years versus ≥3
years; tumor size N mean versus tumor size ≤ mean; tumor grade
poorly-differentiated cells versus well and moderately differentiated
cells; metastasis yes versus no; lymph node metastasis N1-2 versus
N0; and stage III and IV versus I and II.
Cell Culture
HCT-116 cell was obtained from ATCC; RKO, and TP53−/−
derivatives of HCT116 and RKO were obtained from GRCF Cell
Center and Biorepository of John Hopkins University. HCT-116
cells were cultured in DMEM, and RKO cells were cultured in
McCoy 5A, all supplemented with 10% FBS and antibiotics
(Invitrogen). Cells were seeded at density of 105/ml one day prior
to shRNA transfection, lentivirus infection and small-molecule
inhibitor treatment.
RNAi Knockdown and Small-Molecule Inhibitor Experiment
Plasmids each harboring gene-specific or scrambled shRNA
were ordered from the RNAi core, Genomics Research Center,
Academia Sinica. shRNAs were transiently transfected into
isogenic HCT-116 cells using Lipofectamine-2000 (Invitrogen)
following the manufacturer’s protocol, harvested for MTT assay
and RT-PCR 48 hours post-transfection. Isogenic RKO cells were
infected with lentiviruses harboring the shRNAs and harvestedTable 2. List of IHC-stained proteins and the percentages of 171 patients with abnormal IHC.
No. Protein name Criterion of abnormality % of patients
1 ABL1(C) * ≥2+ 56
2 AURKB(C) ≥1+ 94
3 BCR(C) ≥2+ 28
4 BRCA1(C) b1+ 28
5 BRCA2(C) b2+ 32
6 BRCA2(N) * b1+ 34
7 CSNK1E(C) b2+ 54
8 CTNNB1(N) ≥1+ 44
9 MSH2(C) b1+ 8
10 MSH2(N) b1+ 28
11 MYC(N) ≥2+ 83
12 P53(N) ≥1+ 78
13 PARP1(N) ≥1+ 87
14 POLB(N) ≥1+ 66
15 RAD54B(N) ≥1+ 82
16 RB1(N) b1+ 24
17 SGK2(C) b2+ 73
18 SKP2(C) ≥2+ 23
19 WNT5A(C) ≥1+ 60
* The notation (C) and (N) represent cytoplasm and nucleus, respectively.4 days after puromycin selection. Cells were treated with IC261
and D4476 (Sigma) (HCT116 and RKO), and 2,4-Diamino-
Quinazoline (Sigma) (HCT-116) at indicated concentrations.
Cells were harvested for MTT assay 48 hours after treatment. For
The TRC IDs corresponding to the shRNA sequences used please
see Supplementary Materials and Methods.
Real-Time PCR
Real Time PCR was performed using Roche UPL Real Time-PCR
System (Roche) according to manufacturer’s protocol; mRNA
levels were measured using the ΔΔCT method, with beta-actin as
internal control for each sample. For primer sequences and
corresponding UPL probes used please see Supplementary
Materials and Methods.
MTT Assay
MTTassay was performed usingmanufacturer’s protocol (Invitrogen).
Mouse Model Experiment
Animal care in accordance with institutional guidelines and authority
to perform in vivowork was granted by theHomeOffice (ChinaMedical
University). 2 x106 HCT-116 cells (TP53WT andTP53-/-) were injected
subcutaneously into both flanks of groups of five 6- to 7-week old NOD.
CB17-Prkdcscid/JNarlmalemice purchased from theNational Laboratory
Animal Center, Taiwan and treated for eight consecutive days with either
IC261 (20.5mg/kg, dissolved in 5%Kolliphor®EL (Sigma), 5%DMSO,
and 90% PBS) or DMSO 10 days after cell inoculation. Tumor volumes
were measured every day and calculated as tumor width × tumor length ×
tumor height. Significance of the difference in tumor volumewas tested as
described in Supplementary Text S1.
Mantel-Haenszel Log-Rank Test
For each predicted SL pair, we generated Kaplan-Meier survival curves
of the high and low risk groups of patients using the software R, where the
high and low risk groups comprise patients whose paired IHC expression
levels were both abnormal and others, respectively. The log-rank test was
used to calculate the significance of the differences between the survival
curves of the two groups.
Cox Proportional Hazard Regression
For each predicted SL pair and clinicopathological feature, we
computed a P value based on univariate Cox regression model using
global permutation test, which permuted survival time and censor
status simultaneously. We then included IHC of CSNK1E-P53,
CTNNB1-P53, MSH2(C)-RB1 and BRCA1-WNT5A, which were
significantly correlated with survival, four clinicopathological features,
and statuses of chemotherapy treatment and radiation oncology
treatment as covariates to conduct a multivariate Cox regression by
stepwise variable selection (using the software R).
Results
Initial Panel of Candidate Tumor-Dependent Gene Pairs for
Colorectal Cancer
To understand the role that SL pairs play in cancer cells, we first
investigated the gene expression patterns of the known SL pairs
collected. The more closely functionally related a SL pair is, more
frequently the genes may be simultaneously differentially expressed in
cancer cells. We gathered a list of 663 pairs of SL gene pairs verified in
Table 3. The 11 predicted SL pairs which had synergistic effects when correlated with
clinicopathological features.
Protein 1 Protein 2 P value FDR * Log-rank
(P value)
Protein 1 Protein 2 Protein pairs
A. Overall survival
CSNK1E P53 0.065 0.120 0.015 0.467 0.005
CTNNB1 P53 0.346 0.120 0.025 0.467 0.018
CSNK1E MYC 0.065 0.369 0.027 0.467 0.064
ABL1 CSNK1E 0.169 0.065 0.033 0.467 0.066
AURKB CSNK1E 0.524 0.065 0.050 0.467 0.066
B. Tumor size
MSH2(N) POLB 0.069 0.123 0.001 0.168 N/A †
BRCA1 POLB 0.123 0.123 0.022 0.865 N/A
CSNK1E POLB 0.115 0.123 0.045 0.865 N/A
C. Metastasis
MSH2(C) RB1 0.255 0.698 0.001 0.179 N/A
BRCA2 MSH2(C) 0.400 0.255 0.048 0.989 N/A
D. Lymph node metastasis
BRCA1 CSNK1E 0.127 0.268 0.049 1.000 N/A
* FDR was estimated by q-value.
† N/A denotes not applicable.
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wide RNAi screenings [15,16], while the remaining SLs were verified
via individual RNAi knockdown experiments using cancer cell lines
[11,23], most of which were conducted based on hypothesis
generated from pathway information and/or conservation of SLs
from other species.
Validated SL pairs comprise oncogenes, tumor-suppressor genes,
stability genes [2] and others. In general, tumor cells depend on the
overexpression of oncogenes and/or under-expression of tumor
suppressor genes for survival or/and proliferation. Therefore, for each
SL pair we looked for the simultaneously up-regulated pattern
(abbreviated as the [up, up]) one up-regulated and one down-
regulated patterns ([up, down] and [down, up]) and the simulta-
neously down-regulated pattern ([down, down]), where the cutoff of
up- and down-regulation were 1 and -1 in log2 ratio of gene
expression of cancer versus non-cancerous tissues, respectively.
Specifically we computed the percentages of the aforementioned four
patterns of the collected SL gene pairs using the log ratios of gene
expression (see Materials and Methods). To include as many
potential TD pairs as possible, we first included the gene pairs whose
percentages of any of the four patterns were at least one percent.
Because RNAi knockdown is easier than overexpression of a
particular gene, we sorted the gene pairs by the percentages of the
(up, up), (up, down), (down, up), and then (down, down) patterns to
result in Table 1, which included genes highly mutated in CRC such
as TP53 [26] (see Materials and Methods).
Although the over-expression of tumor-suppressor and stability
gene pairs, e.g., DNA repair and checkpoint classes, in Table 1 seems
surprising at first glance, it is consistent with the drastic increase in
genomic instability and DNA replication caused by mutant
oncogenes such as KRAS and MYC.
Correlating IHC Stainings of TD Pairs With
Clinicopathological Features Identifies SL Pairs
We first filtered out FEN1, KRAS and PTEN from the candidates in
Table 1 resulting in 17 genes for IHC staining. FEN1 was not chosen
because no isogenic FEN1 mutant CRC cell line is available. KRAS and
PTEN were omitted because we aimed to uncover novel SL pairs, and
multiple SL targets of KRAS and PTEN have been identified through
genome-wide RNAi screening [15,16] and small-molecule library
screening, respectively [27]. IHCs of these remaining 17 proteins at
multiple cellular locations were conducted (Table 2, Supplementary
Figure W2) to confirm the trends of their mRNA expression using CRC
tissues dissected from 171 patients from Changhua Christian Hospital,
Changhua City, Taiwan (Supplementary Table W2, see Materials
and Methods).
To extend the analysis beyond the protein pairs listed in
Table 1, we then considered all possible pairs (169 pairs) of
proteins, from the 19 candidates in Table 2 (excluding the pairs of
the same protein stained in different cellular locations). Note that
this procedure allows novel SL pairs to be included in this study,
which is essential for uncovering novel SL pairs. To see how the
TD pairs were related to the phenotypes of CRC, we correlated
IHCs of each of these 169 protein pairs with five clinicopatho-
logical features of the patients: overall survival, tumor size,
histological grade, lymph node metastasis, and metastasis. Please
note for simplicity, henceforth we have omitted the location attached to
the protein name, e.g., CSNK1E(C) is written as CSNK1E, unless
ambiguity arises.A pair of proteins is called to have a synergistic effect if their paired
abnormal IHCs are significantly correlated (P b 0.05; Fisher’s exact test)
with a clinicopathological feature (e.g., overall survival), but the
abnormal IHC of each single protein is not. Any protein pair passing
this synergy screening was predicted to be SLs, because this synergistic
effect implies that abnormal IHCs of a protein pair is associated with a
cancer phenotype (e.g., a poor overall survival), but the abnormal IHC
of each individual protein is not. In other words, CRC cells seem to
depend on each of these protein pairs, but not each individual protein,
for maintenance of viability. Thus, simultaneous mutation of each TD
pair may eliminate the tumor cells, which is synthetic lethality. Note
that inmodel organisms [6,8,9], coexpression and phenotype have been
shown to be useful in predicting SL interactions. However, the
proposed synergistic effect is novel in (1) prioritizing the gene pairs co-
expressed in cancer cells and (2) correlating their IHC expression to
clinicopathological features (served as phenotypes) of CRC patients.
Correlating the paired and individual IHCs of 169 protein pairs to
each of the five clinicopathological features resulted in 11 predicted
SL pairs (Table 3); Fisher’s exact test (see Materials and Methods) was
applied to test the significance of the correlation (P b 0.05), and the
false discovery rate of a test was estimated by the q-value (qvalue in R),
which measured the proportion of false positives incurred when the
test was claimed significant (those with P b 0.05) [24]. The complete
results are shown in Supplementary Table W4.
We first checked the 11 predicted SL pairs (Table 3) against the
literature (searched up to February 2014). Out of these predicted SL
pairs, two pairs MSH2-POLB and CSNK1E-MYC are known SL
pairs, and have been validated in cell lines [28] and via large scale
RNAi screening [17], respectively. The gene expression of CSNK1E
was shown to be associated with that of MYC in colon cancer.
Because CSNK1E was implicated in cancer only recently [17], these
findings demonstrate that our method is able to uncover SL gene pairs
without being limited by pathway information or without prior
knowledge of whether a target gene is involved in cancer.
Table 3 shows that correlating IHCs of the protein pairs to overall
survival resulted in the largest number of predicted SL pairs, and included
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(Table 3 in [26]) and is mutant in about half of all cancers. Further, the
fact that CSNK1E-MYC ranked third in Table 3A was a verified SL pair
suggested that the top-two pairs in Table 3A, CSNK1E-P53 and
CTNNB1-TP53may be novel SL pairs; we validated these using RNAi,
small-molecule inhibitor and mouse model as follows.
A rule of thumb for prioritizing predicted SL pairs for validation: first,
incorporating prior knowledge, e.g., known SL pairs or/and pathway
information. Second, using biological importance, e.g., those having
frequentlymutated cancer genes in the cancer of interest will be on top of
the list.Figure 1. RNAi knockdown of CSNK1E (A and B) and CTNNB1 (C and D
assay. Relative mRNA expression level was measured using the co
internal control. Relative viability of HCT-116 andRKOcells (TP53WT an
or (C) CTNNB1-targeting shRNAs (#1 and #2), and control shRNA. Re
targeting shRNAs (#1 and #2) or (D) CTNNB1 following transfectio
Relative viability of cells (TP53WT and TP53-/-) following treatment with
and TP53-/-) following treatment with D4476 in (G) HCT-116 and (H) RCSNK1E and CTNNB1 are Validated as SL to TP53 by
RNAi Knockdown (CTNNB1 with TP53), Small-Molecule
Inhibition and In Vivo Model (CSN1KE with TP53)
We selected two pairs of isogenic CRC cell lines, HCT-116 and
RKO, varying only in TP53 status (TP53WT and TP53 -/-), as in vitro
models to validate that TP53- CSNK1E and TP53-CTNNB1 are SL
pairs.We transiently transfectedHCT-116 cells and infected RKO cells
with lentiviruses with shRNAs targeting CSNK1E (CSNK1E-1 and
CSNK1E-2) and CTNNB1 (CTNNB1-1 and CTNNB1-2). Knock-
down of each gene markedly reduced the viability of TP53−/− cells as
compared to TP53WT cells (Figure 1A-D, for details please see) selectively killed TP53−/− cells. Cell viability wasmeasured byMTT
mparative CT (ΔΔCT) method; beta-actin mRNA was used as an
d TP53-/-) transfectedwith (A)CSNK1E-targeting shRNAs (#1 and#2)
lative mRNA level of (B) CSNK1E following transfection of CSNK1E-
n of CTNNB1-targeting shRNAs (#1 and #2), and control shRNA.
IC261 in (E) HCT-116 and (F) RKO. Relative viability of cells (TP53WT
KO.
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approach is suitable for the effective prediction of SL gene pairs. The
other predicted SL pairs shown in Table 3 are also promising and could
be validated in the future.
To evaluate the specificity and efficacy of small-molecule inhibitors of
CSNK1E and CTNNB1 in killing TP53−/− cells, we treated the
aforementioned cell lines with inhibitors of CSNK1E, IC261 andD4476
(Figure 1E-H). Upon treatment with IC261, we observed a reduction in
cell viability in TP53−/− HCT-116 cells (IC50 of 1.37 μmol/L as
compared to 8.30μmol/L, whichwas about 6-fold higher); in RKOcells,
about 1.8-fold difference in IC50 was observed (0.62 μmol/L as
compared to 0.34 μmol/L; Figure 1E and F). Treatment with D4476
yielded similar fold changes of IC50 of TP53
WT cells and TP53−/− cells
(about 4.7-fold) in both cell lines (250.72 μmol/L as compared to
53.22 μmol/L for HCT116 cells, 60.79 μmol/L as compared to
12.76 μmol/L for RKO cells; Figure 1G and H). However, treatment of
2,4-Diamino-Quinazoline (inhibitor of CTNNB1) in HCT-116 cells
did not exhibit selective toxicity againstTP53−/− cells (IC50 of 995μmol/L
and 821 μmol/L for TP53WT cells and TP53−/− cells, respectively). We
wonder whether this is due to the non-specific targeting of 2.4-Diamino-
Quinazoline, which targets the CTNNB1/TCF complex. Since IC261
andD4476were shown to inhibit microtubule polymerization [29] and
ALK5 (transforming growth factor beta1 type I receptor) [30],
respectively, the use of these compounds to asses the physiological
role of CSNK1E needs to be cautiously interpreted.
We further evaluated the efficacy of IC261 in an in vivo preclinical
model. TP5WT (TP53-/-) HCT-116 cells were injected subcutane-
ously into the right (left) flank of groups of five NOD/SCID mice
and allowed to grow for 10 days (tumor volumes ranged from
12.50 mm3 to 41.72 mm3 and 13.02 mm3 to 48.19 mm3 for
TP53WT and TP53−/− tumor xenografts on the 10th day,
respectively). Subjects were then treated for nine consecutive days
with either IC261 or DMSO before sacrifice. Tumor volumes were
recorded daily after the start of the treatment.Figure 2. IC261 treatment inhibited TP53−/− tumor growth in vivo. (A
(image for each treatment was the same mouse) in NOD/SCID mice a
the treatment regimen with IC261 and DMSO control (n= 5 for each
P b 0.05).At the end of experiment, tumor volumes ranged from165.60mm3 to
487.20 mm3 and 195.86 mm3 to 725.91 mm3 for DMSO-treated
TP53WT andTP53−/− tumor xenografts, respectively. For IC261-treated
mice, tumor volumes ranging from 50.82 mm3 to 250.88 mm3 and
25.67 mm3 to 342.90 mm3 were observed for TP53WT and TP53−/−
tumor xenografts, respectively.
For each day, the tumor volumes of five TP53WT xenografts were
adjusted to their mean ðTP53WT Þ of the same day. Two sample
t-test was conducted using TP53−/− xenograft tumor volumes under
treatment IC261 versus DMSO, calibrated according to the volumes of
theirTP53WT counterparts, to test the hypothesis that tumor volumes of
IC261-treated TP53−/− xenografts were less than their DMSO-treated
counterpart based on the definition of synthetic lethality. Calibrated
TP53−/− xenograft tumor volumes were 490.93 mm3 ± 323.35 mm3
and 138.03 mm3 ± 79.56mm3, for DMSO-treated and IC261-treated
samples, respectively (for details, please see Supplementary Text S1).
Consistent with our in vitro data, IC261-treated HCT-116
TP53−/− tumor (n = 5) in NOD/SCID mice showed markedly
reduced tumor formation (Figure 2) as compared to the
corresponding treatment with DMSO (n = 5), with the last three
tumor volume differences of about 2.0-, 2.4- and 3.6-fold,
respectively (P value = 0.033, 0.045, 0.023, for the last three
days, respectively; two-sample t-test). Additionally, our preventive
model, by pre-treating TP53−/− cells with DMSO and IC261
before cell inoculation, also showed selective inhibition of TP53−/−
tumor growth by IC261 (Supplementary Materials and Methods
and Supplementary Figure W3).
CSNK1E-P53, CTNNB1-P53, MSH2(C)-RB1 and BRCA1-
WNT5A are Correlated with Poor Prognosis
Prognosis provides patients with information to make decisions
about adopting further treatments, thus it is important in clinical
medicine. The results of the log-rank test in Supplementary Table) Representative images of xenografts obtained with HCT-116 cells
fter treatment with either DMSO or IC261. (B) Mean tumor size over
group, error bars indicate standard error, the notation * indicates
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IHCs of CSNK1E-P53, CTNNB1-P53, MSH2(C)-RB1 or
BRCA1-WNT5A had a significantly different survival curve than
that of patients in the remaining subgroup (P = 0.005, 0.018, 0.002
and 0.041, respectively; Mantel-Haenszel log-rank test; see
Materials and Methods).
Kaplan-Meier survival analysis was performed, and the estimated
survival curves of patients with abnormal IHCs for each of these four
pairs was indeed separated from that of the remaining subgroup
(Figure 3). Interestingly, none of individual IHC of CSNK1E, P53,
CTNNB1, MSH2(C), RB1, BRCA1 or WNT5A could separate the
estimated survival curves of patients into two subgroups (P = 0.067,
0.119, 0.536, 0.338, 0.374, 0.118 and 0.510, respectively; log-rank
test; Supplementary Figure W4).
CSNK1E-P53, CTNNB1-P53, MSH2(C)-RB1,
BRCA1-WNT5A are Independent Prognosis Markers
from Stage for CRC Patient Survival
Potential prognostic markers can be identified from gene,
microRNA or protein expression data [31–34]. We further
investigated which IHC of the 169 protein pairs were correlated
with CRC patient survival, because no IHC of any individual protein
was significantly correlated with overall survival. A univariate Cox
proportional hazard regression analysis, applied to an independentFigure 3. Abnormal IHCs of the four protein pairs are correlated with p
by the paired IHCs of (A) CSNK1E and P53, (B) CTNNB1and P53, (C)
patients with paired abnormal IHCs are plotted in solid line and the cur
“-” denotes abnormal IHC of the corresponding protein.cohort of 171 CRC patients, suggested that IHC of CSNK1E↓-P53↑,
MSH2(C)↓-RB1↓, CTNNB↑1-P53↑ and BRCA1↓-WNT5A↑ (the
symbols “↑”and “↓”denoting abnormal IHC [overexpression and
underexpression, respectively] of the corresponding protein) were
relevant prognosis factors with P values equal to 0.006, 0.015, 0.018
and 0.047, respectively [32,33] (see Materials and Methods); see
Supplementary Table W5 for the complete results. Moreover, survival
analysis of four clinical factors indicated that stage was correlated with
survival (P = 0.034), while age, sex and grade were not (P = 0.289,
0.351, 0.466, respectively).
Subsequently, a multivariate Cox proportional hazard regression
analysis, with stepwise variable selection, was applied to IHCs of the
aforementioned four protein pairs, the four clinicopathological factors
and the statuses of chemotherapy treatment (CT) and radiation
treatment (RT) [32,33]; age, grade, CT and RT statuses were filtered
out in the first four steps.
The four protein pairs and stage were found to be significantly
associated with patient survival (P = 0.001, 0.007, 0.027, 0.010 and
0.010, respectively; with hazard ratio = 7.53, 1.65, 1.50, 1.93 and
1.58, respectively; Table 4). Another multivariate Cox regression
model applied to the five significant factors excluding CTNNB1-P53
resulted in about the same hazard rates for these factors as shown in
Table 4 (with minor changes in the first decimal places); the result
was similar when CSNK1E-P53 was deleted. Thus, the correlationoor prognosis Kaplan-Meier survival curves of CRC patients divided
MSH2(C) and RB1, and (D) BRCA1 and WNT5A. The curves for the
ves of the remaining patients are plotted in dashed line; the symbol
Table 4.Overall survival of 171 CRC patients in relation to clinical factors and IHC of protein pairs.
A. Univariate Cox regression
Variable Subset Hazard ratio (95% CI) P value
Age age N65/age b = 65 1.19 (0.86-1.66) 0.289
Gender male/female 1.17 (0.84-1.63) 0.351
Grade poor/well and moderate 1.27 (0.67-2.42) 0.466
Stage III-IV/I-II 1.42 (1.03-1.97) 0.033
(MSH2(C), RB1(N)) (↓,↓) */otherwise 4.34 (1.58-11.95) 0.015
(CSNK1E(C), P53(N)) (↓,↑)/otherwise 1.62 (1.15-2.26) 0.006
(CTNNB1(N), P53(N)) (↑,↑)/otherwise 1.50 (1.07-2.09) 0.018
(BRCA1(C), WNT5A(C)) (↓,↑)/otherwise 1.64 (1.02-2.63) 0.047
B. Multivariate Cox regression †
Variable Subset Hazard ratio (95% CI) P value
Stage III-IV/I-II 1.58 (1.11-2.24) 0.010
(MSH2(C), RB1(N)) (↓,↓) */otherwise 7.53 (2.25-25.24) 0.001
(CSNK1E(C), P53(N)) (↓,↑)/otherwise 1.65 (1.14-2.38) 0.007
(CTNNB1(N), P53(N)) (↑,↑)/otherwise 1.50 (1.05-2.14) 0.027
(BRCA1(C), WNT5A(C)) (↓,↑)/otherwise 1.93 (1.17-3.19) 0.010
* The symbols “↑”and “↓”denote abnormal IHC (overexpression and underexpression, respectively) of the
corresponding protein.
† Variables were selected by using stepwise selection method.
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ratio result.
CSNK1E-P53 is an Early-Stage Prognosis Marker While the
Remaining Three Protein Pairs areMarkers Throughout the Stages
These four protein pairs and stage are independent prognostic
factors, thus the former could serve as markers for CRC patient
survival. We further studied whether these four paired markers
depended on stage or not as follows. Each pair of IHC, stage and their
interaction was fitted by a multivariate Cox regression model, which
resulted in CSNK1E-P53 being dependent on stage. Note that this
pair is an early-stage prognosis marker (both Stage I-II and Stage I-III)
(P = 0.032 and 0.007, n = 86 and 141, respectively; log-rank test). For
details, please refer to Supplementary Table W6 and Figure W5.
Discussion
We have developed a cost-effective approach to uncover SL gene pairs
for therapeutics of CRC, which predicted SL pairs efficiently via
finding synergistic correlation of IHC (protein) pairs with clinico-
pathological factors (phenotypes) of CRC patients. Of the 11
predicted SL pairs, MSH2-POLB and CSNK1E-MYC were known
SL in human, and we further validated CSNK1E-TP53 and
CTNNB1-TP53. Our method suggested that clinical factors may
be used as phenotypes to predict synthetic lethality. In addition,
MSH2-RB1was previously implied as SL in amouse study [35]. The study
demonstrated thatmouse with deficiency in bothMSH2 andRB1 showed
delayed development of lymphoma, associated with increased apoptosis of
lymphoma cells, as compared to MSH2-deficient mice. With rich
repertoire of public domain gene expression data (e.g. The Cancer
Genome Atlas), commercially available tissue arrays with clinical data, it is
conceivable that our approach can be applied to other cancers in the future.
While safety regarding inhibition of TP53 is controversial [36], our
validation of CSNK1E as SL to TP53 in vitro (further supported by a
previous study in mouse MEF cells [37]) and in vivo showed that this
pair may be translated to preclinical study. Note that IC261, the
inhibitor of CSNK1E used in both in vitro and in vivo studies alsoinhibitedmicrotubule polymerization [29], whichmay lead to increased
cancer cell death [38]. However, in our in vivo study the IC261-treated
TP53−/− xenograft tumor volumes were calibrated to the volumes of
their TP53WT counterparts, which adjusted the effect of microtubule
polymerization, and the IC261-treated tumors still shrunk more
significantly than the DMSO-treated ones. This suggests that
synthetic lethality between TP53 and CSNK1E plays a significant
role in killing cancer cells. CSNK1E and CTNNB1 are both known
components of WNT signaling pathway. Both activated WNT
signaling [39] and TP53 inactivation [40] are frequently implicated
in cancer tumorigenesis. Previous study showed that loss of TP53
lead to activation of WNT signaling pathway, mediated through
miR-34 [41], suggesting that our result is consistent with current
literature regarding synthetic lethality, which arises primarily from
compensatory pathways [4], thus implying a buffering relationship
between p53 and WNT signaling pathway in CRC. Since TP53 is
mutated in half of all cancers, CSNK1E may be a promising
druggable target for a broad population of TP53-mutant patients.
CSNK1E↓-P53↑, MSH2(C)↓-RB1↓, CTNNB↑1-P53↑ and
BRCA1↓-WNT5A↑ were revealed to be prognosis markers, with
the first pair for early-stage and the remaining for all stages,
independent from stage for CRC, but interestingly none of ~20
individual IHC was correlated with overall survival. Previous studies
identified prognostic markers via cellular phenotypes (such as cell
differentiation) [42] and protein pairs [43], separately, through
insights from pathway information, while our approach identified
markers without requiring prior knowledge of molecular mechanism.
Finally, our method can be extended as follows. First, we can pair a
gene of interest, preferably a frequently mutated gene in cancers, with
the remaining genes in human genome to constitute the initial panel
and the remaining procedures follow similarly. Second, this approach
can be applied to several cancers to predict their unique/common SL
pairs and prognosis markers.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.neo.2014.04.007.
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